Sun Pharmaceutical share price, financials and monitoring
Sun Pharmaceutical Industries is a diversified drug company with India formulations, US specialty products, generics and emerging-market operations. Sales growth needs to be separated by market and product type, then read with R&D, regulatory events, launches, margins and cash conversion.
FY26 and the latest quarter
The annual and quarterly numbers below come from the current point-in-time serving views. Consolidated results are preferred and the source is retained where it is publicly linkable.
Revenue history
A rising top line is evidence of scale, not proof of value creation. Read it with profit, capital efficiency, cash conversion and the business-specific guideposts above.
₹ crore values are presented as filed or normalized from company/exchange financial results. Banks and NBFCs use total income because interest is part of their operating business. Industrial companies use revenue where available.
Historical values can be restated. This page shows the current serving vintage and preserves the source and reporting basis.
| Fiscal year | Revenue | PAT | EPS | Basis | Evidence |
|---|---|---|---|---|---|
| FY2231 Mar 2022 | ₹38,654 cr | ₹3,389 cr | 13.6 | Consolidated | Filing ↗ |
| FY2331 Mar 2023 | ₹43,886 cr | ₹8,513 cr | 35.3 | Consolidated | Filing ↗ |
| FY2431 Mar 2024 | ₹48,497 cr | ₹9,610 cr | 39.9 | Consolidated | Filing ↗ |
| FY2531 Mar 2025 | ₹52,578 cr | ₹10,965 cr | 45.6 | Consolidated | Filing ↗ |
| FY2631 Mar 2026 | ₹58,462 cr | ₹11,509 cr | 47.8 | Consolidated | Filing ↗ |
Eight reported quarters
Publication date is shown separately from the period end. A June quarter was not knowable on 30 June; it entered the public record only when the company filed it.
| Quarter ended | Revenue | Attributable PAT | EPS | Published | Evidence |
|---|---|---|---|---|---|
| 30 Jun 2026Consolidated | ₹15,300 cr | ₹2,895 cr | 12.1 | 31 Jul 2026 | Filing ↗ |
| 31 Mar 2026Consolidated | ₹14,612 cr | ₹2,714 cr | 11.3 | 22 May 2026 | Filing ↗ |
| 31 Dec 2025Consolidated | ₹15,521 cr | ₹3,369 cr | 14 | 31 Jan 2026 | Filing ↗ |
| 30 Sept 2025Consolidated | ₹14,478 cr | ₹3,118 cr | 13 | 5 Nov 2025 | Filing ↗ |
| 30 Jun 2025Consolidated | ₹13,851 cr | ₹2,279 cr | 9.5 | 31 Jul 2025 | Filing ↗ |
| 31 Mar 2025Consolidated | ₹12,959 cr | ₹2,150 cr | 9 | 22 May 2025 | Filing ↗ |
| 31 Dec 2024Consolidated | ₹13,675 cr | ₹2,903 cr | 12.1 | 31 Jan 2025 | Filing ↗ |
| 30 Sept 2024Consolidated | ₹13,291 cr | ₹3,040 cr | 12.7 | 28 Oct 2024 | Filing ↗ |
Use the metric that fits the business.
ROCE is not shown for banks and NBFCs because deposits and borrowings are operating raw material rather than ordinary financing. Missing or inapplicable values remain unavailable.
Who owns the company?
Shareholding is shown from the latest available filing. Institutional subtotals depend on the filing taxonomy and are labelled by their source basis.
Profit is only one part of the evidence.
These are investigation prompts, not pass-or-fail verdicts. Business model, working-capital structure and reporting basis determine how each value should be interpreted.
Current, sourced and intentionally finite.
This public page contains a selected, licensable subset of Altys company data. It does not expose private research notes, broker documents, user portfolios or the company database.
Related company and methodology pages
Sun Pharmaceutical FAQ
What does Sun Pharmaceutical do?
Sun Pharmaceutical Industries is a diversified drug company with India formulations, US specialty products, generics and emerging-market operations. Sales growth needs to be separated by market and product type, then read with R&D, regulatory events, launches, margins and cash conversion.
What should investors monitor for Sun Pharmaceutical?
Important operating evidence includes india formulation growth, us specialty sales, product launches, r&d spending, regulatory observations, margins and cash conversion. These are research guideposts, not automatic trading signals.
Are the Sun Pharmaceutical financials consolidated or standalone?
Altys prefers consolidated financials when available and labels the reporting basis in each table. The latest annual row on this page is consolidated.
Does Altys recommend buying or selling Sun Pharmaceutical?
No. Altys provides sourced financial data, research context and monitoring infrastructure. It does not issue a buy, sell or hold recommendation on this page.
Research Sun Pharmaceutical once. Keep watching what changes.
Altys can connect new results, filings, concalls, guidance, ownership and company-specific KPIs with the investment team’s original thesis and portfolio context.